Evelo Biosciences' lead drug candidate has failed a midstage trial in atopic dermatitis, wreaking havoc with its share price, but the biotech says it still plans to go ahe
Shares in French biotech Inventiva were on the slide this morning after AbbVie revealed that it had decided to abandon development of cedirogant, their drug candidate for autoimmune disease
Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb's much-touted rival deucravacitinib, w
The FDA has kicked off its review of Bristol-Myers Squibb's psoriasis therapy deucravacitinib, setting an action date of 1 September next year, as the EU and Japanese regulators also start
Our website has served us well over the years, but after five years since the last re-design – during which aesthetic standards have changed and website technology has improved